*Short Course requires separate registration
You do not need to be registered for full conference to attend
Federal and state biosimilar adoption policies impact stakeholders across the spectrum from research to commercialization to patients and their health care providers. An understanding of the complex policy environment, and how they interact, is necessary to ensure success of biosimilars’ as part of a sustainable multisource market in the US.
This boot camp will provide a high-level overview of current and proposed biosimilar policies in the United States. This boot camp will also provide an opportunity for participants to engage with panelists and each other to have questions answered and provide feedback on the needs for further insight and education. It will be explicitly cross-disciplinary and integrate answers to questions from clinical, regulatory, legislative, and international perspectives. You should expect debate and discussion as we consider recent federal and state initiatives on misinformation in biosimilar communications, the potential for insulin biosimilars, and the coming wave of pharmacy benefit biosimilars, and the consequences for critical classes of products that are front and central to the current discussion on access for affordable medications.
12:00-12:45PM: Key Policy Updates Impacting Biosimilars
12:45-1:45PM: The New Normal and Biosimilars’ Policy: What is the Impact to the Health Care System?
Moderator: Anna Rose Welch, MA, Chief Editor, Biosimilar Development, Life Science Connect
2:00-3:00PM: Other Key Policy Issues
- Issues Related to Misinformation
- What’s Needed to Ensure Success in Insulin Biosimilars?